Last reviewed · How we verify
Metoprolol XL
At a glance
| Generic name | Metoprolol XL |
|---|---|
| Also known as | Toprol XL, Metoprolol, Seloken ZOC tablets, Toprol-XL, Metolar XL |
| Sponsor | Emory University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score (PHASE4)
- Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects (PHASE4)
- Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart (PHASE4)
- Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure (PHASE2)
- Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (PHASE3)
- Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients (PHASE4)
- 307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects (PHASE3)
- Nebivolol and Endothelial Regulation of Fibrinolysis (NERF) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metoprolol XL CI brief — competitive landscape report
- Metoprolol XL updates RSS · CI watch RSS
- Emory University portfolio CI